Woolley P V, Schultz C J, Rodriguez G I, Gams R A, Rowe K W, Dadey M L, Von Hoff D D, McPhillips J J
Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center, Lee Hospital, Johnstown, PA, USA.
Invest New Drugs. 1996;14(2):219-22. doi: 10.1007/BF00210794.
We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone marrow suppression was seen. No tumor regressions occurred in 14 evaluable patients including 5 with no prior therapy. We conclude that ilmofosine is inactive in this tumor at this dose and schedule.
我们使用连续输注5天、剂量为300mg/m²/天的方案，对异环磷酰胺（1-十六烷基硫基；2-甲氧基乙基-消旋甘油-3-磷酸胆碱）在非小细胞支气管癌中的应用进行了研究。毒性反应包括胃肠道反应（恶心、呕吐、腹泻）、疲劳和肝功能异常。这些反应较为严重，导致一些患者退出研究。未观察到一致的骨髓抑制模式。在14例可评估患者中，包括5例未接受过先前治疗的患者，均未出现肿瘤消退。我们得出结论，在此剂量和方案下，异环磷酰胺对该肿瘤无效。
